Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

EU approves Moderna's Spikevax, targeting LP.8.1 SARS-CoV-2, for coronavirus disease in patients from 6 months
Vaccine, infectious disease, mRNA vaccine, COVID-19, variant-specific, pediatric use - Read more

FDA approves Novo Nordisk's Alhemo®, TFPI-targeting therapy, for hemophilia A/B without inhibitors in Ph3 success
Monoclonal antibody, hemophilia, TFPI inhibitor, subcutaneous administration - Read more

FDA approves LENZ Therapeutics' VIZZ (aceclidine) eye drops for presbyopia in adults
Small molecule, ophthalmic, eye drops, presbyopia, age-related vision loss, miotic agent - Read more

NextCure seeks partners for NC605 antibody showing promise in brittle bone disease mouse models
Research collaboration, rare disease, antibody, R&D, licensing deal - Read more

Evotec sells French biosimilars facility to Sandoz for $300M, advancing asset-lighter manufacturing strategy
Manufacturing agreement, biosimilars, facility acquisition, biologics manufacturing, continuous manufacturing, milestone payments - Read more

MaxCyte, Anocca AB partner on TCR-T therapies; MaxCyte to receive licensing fees for electroporation platform technology
Licensing deal, cell therapy, oncology, manufacturing, T-cell therapy - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

ImmuneOnco reports promising Ph2 data for IMM2510, PD-L1xVEGF bispecific, in non-small cell lung cancer
Antibody, cancer, bispecific antibody, non-small cell lung cancer, PD-L1, VEGF, combination therapy - Read more

Soligenix's SGX945 demonstrates efficacy in Ph2 trial for Behçet's Disease, matching apremilast in oral ulcer treatment
Small molecule, autoimmune, Behçet's Disease, oral ulcers, dusquetide, rare disease - Read more

Eli Lilly's Ph3 data shows Kisunla maintains amyloid clearance in Alzheimer's disease patients after treatment discontinuation.
Antibody, neurological, monoclonal antibody, Alzheimer disease, amyloid plaque, disease progression - Read more

Eli Lilly's Mounjaro demonstrates heart health benefits in Ph3 trial for Type 2 diabetes patients
Small molecule, metabolic, GLP-1 receptor agonist, Type 2 diabetes, cardiovascular, obesity - Read more

Biogen raises sales outlook as Leqembi grows and awaits FDA decision on subcutaneous autoinjector option
Monoclonal antibody, Alzheimer's disease, financial, regulatory, commercial growth - Read more

Alnylam's rare disease drug Amvuttra smashes sales forecasts, boosting market cap above $50 billion
RNAi therapeutic, rare disease, financial, revenue impact - Read more

Biogen reports Leqembi sales growth of 58% globally as blood-based biomarker tests ease Alzheimer's treatment access
Monoclonal antibody, Alzheimer's disease, neurological, financial, strategic - Read more

AbbVie's Skyrizi and Rinvoq sales soar to $6.4B, expected to surpass Humira's peak revenue
Monoclonal antibody, autoimmune, financial, strategic, competitive - Read more

Sanofi CFO: Tariffs will have minimal financial impact in 2025 due to existing US inventory
Monoclonal antibody, autoimmune, financial, operational, regulatory - Read more

Sanofi's Q2 sales hit €10B ($11.43B) as Dupixent surges 21%, despite rising R&D expenses
Monoclonal antibody, autoimmune, financial, operational, R&D investment - Read more

Frazier Life Sciences raises $1.3B venture fund for early-stage biotech investing and company creation
Venture capital, early-stage biotech, oncology, drug discovery, platform technology - Read more

Prime Medicine raises $125.4M public offering, advancing curative genetic therapies
Gene therapy, platform technology, genetic therapies, rare disease, cystic fibrosis, preclinical - Read more

Rein Therapeutics raises $21M flexible financing to advance pulmonary fibrosis clinical trials
Pulmonary disease, fibrosis, orphan indications, small molecule, clinical-stage - Read more

PL BioScience expands headquarters to become world's largest Human Platelet Lysate producer with 20,000L capacity
Cell culture supplements, strategic, operational, manufacturing expansion, supply chain - Read more

AbbVie reportedly pursuing $1B acquisition of Gilgamesh Pharmaceuticals to strengthen neuroscience portfolio amid strong earnings
Psychedelic compound, neuropsychiatry, strategic acquisition, portfolio expansion - Read more

ESTEVE acquires U.S.-based Regis Technologies, expanding American CDMO presence for small-molecule API development
Small molecule, CDMO, strategic acquisition, manufacturing capabilities, international expansion - Read more

HHS launches pilot program testing drugmaker-managed rebates for 340B drugs starting 2026
Healthcare policy, drug pricing, operational, regulatory, financial - Read more

Prasad's FDA departure signals potential shift towards looser cell and gene therapy regulation
Cell and gene therapy, regulatory, policy shift, political impact - Read more

Nuvectis discontinues Ph1b GCN2 kinase activator NXP800 for ovarian cancer after limited efficacy data
Small molecule, cancer, kinase inhibitor, ovarian cancer, clinical trial failure, ARID1a mutation - Read more

AbbVie's lutikizumab fails Ph2 trial in ulcerative colitis, missing efficacy targets as IL-1 monotherapy
Protein therapy, autoimmune, monoclonal antibody, inflammatory bowel disease, IL-1 inhibitor, combination therapy - Read more

Bristol Myers Squibb's Cobenfy future uncertain after Phase III failure; Alzheimer's psychosis trials ongoing
Small molecule, neurological, schizophrenia, Alzheimer's psychosis, regulatory, strategic - Read more

Merck & Co. slashes 6,000 jobs (8% of workforce) amid $3 billion cost-cutting initiative ahead of Keytruda biosimilar competition
Strategic, cost reduction, operational, financial - Read more

Moderna to cut 10% of workforce amid declining vaccine sales and cost-reduction efforts
mRNA vaccine, infectious disease, operational, cost reduction, financial - Read more

FDA halts Allogene Therapeutics's ALLO-647 anti-CD52 antibody in Ph3 trial following patient death in large B-cell lymphoma
Cell therapy, cancer, CAR-T, large B-cell lymphoma, allogeneic, lymphodepletion - Read more

Kennedy's CDC panel overhaul prompts ousted vaccine experts to call for alternative advisory system
Vaccines, infectious disease, regulatory, policy change - Read more

Trump threatens drugmakers with "every tool" if they don't lower US prices to international levels
Drug pricing, pharmaceutical policy, financial, regulatory, competitive - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here